Regeneron (REGN) Beats Estimates, Fueled by Covid Therapy and Eylea
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- AppLovin gains market share among e-commerce advertisers
- Wall Street ends higher as investors turn to earnings season
Regeneron (REGN) Results Highlight Strong Fundamentals, Focus Remains on Novel Product Readouts - BMO Capital
February 4, 2022 3:04 PM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $780.00 price target on Regeneron Pharma (NASDAQ: REGN), following the company's recent quarterly report.
The analyst quotes: "Key products continuing strong growth; all eyes to pipeline execution. FY2021 results highlighted the strong... More
Regeneron Pharma (REGN) PT Raised to $640 at Cowen
February 4, 2022 12:55 PM ESTCowen analyst Tyler Van Buren raised the price target on Regeneron Pharma (NASDAQ: REGN) to $640.00 (from $625.00) while maintaining a Market Perform rating following reuslts.
The analyst commented, "A strong commercial performance of the core business led to strong Q4 results. Understanding... More
